Cell and Gene Therapy Manufacturing Services Market Size and Share Analysis - Growth Trends and Forecasts (2026-2033)

Market Size and Trends

The Cell and Gene Therapy Manufacturing Services market is estimated to be valued at USD 8.5 billion in 2026 and is expected to reach USD 21.3 billion by 2033, growing at a compound annual growth rate (CAGR) of 13.7% from 2026 to 2033. This substantial growth is driven by increasing advancements in gene editing technologies, rising demand for personalized medicine, and expanding applications of cell and gene therapies in treating complex diseases across oncology, genetic disorders, and regenerative medicine.

Market trends indicate a significant shift towards automation and scalable manufacturing processes to meet growing demand while ensuring high quality and regulatory compliance. Additionally, strategic collaborations between biopharmaceutical companies and contract manufacturing organizations (CMOs) are becoming more prevalent, enabling faster development and commercialization of innovative therapies. The integration of digital technologies such as AI and data analytics further optimizes production efficiency and cost-effectiveness, fueling market expansion and driving innovation in the cell and gene therapy manufacturing ecosystem.

Segmental Analysis:

By Therapy Type: Dominance of Cell Therapy Driven by Clinical Advancements and Demand for Personalized Treatment

In terms of By Therapy Type, Cell Therapy contributes the highest share of the Cell and Gene Therapy Manufacturing Services market owing to its rapidly growing adoption in treating a broad spectrum of diseases, including cancers, autoimmune disorders, and rare genetic conditions. The increasing success of chimeric antigen receptor T-cell (CAR-T) therapies has propelled cell therapy to the forefront, as it provides highly personalized treatment approaches tailored to individual patient profiles. The complex nature of cell therapy requiring harvesting, modification, and reinfusion of living cells necessitates sophisticated manufacturing processes, thereby fueling demand for specialized manufacturing services. Further supporting growth is the expansion of clinical trials targeting cell-based interventions, which ensures a steady influx of product candidates requiring scalable and compliant manufacture. Additionally, advances in automation and closed-system processing have improved manufacturing efficiencies, helping to overcome previous production bottlenecks. The regulatory landscape has also matured, with clearer guidelines encouraging more companies to invest in cell therapy development, enhancing market confidence. Combination therapies that integrate cell and gene approaches, while showing promise, still trail cell therapy due to technical challenges and higher development complexities. Other modalities remain niche and exploratory, with limited contributions as they await validation through clinical outcomes. Taken together, these factors position cell therapy as the dominant segment driven by unmet medical needs, clinical breakthroughs, and evolving manufacturing technologies.

By Process Type: Upstream Processing Leads Due to Critical Role in Ensuring Product Quality and Yield

By Process Type, Upstream Processing holds the largest share within the manufacturing services ecosystem as it encompasses the vital initial stages of cell and gene therapy production, including cell culture expansion, genetic modification, and viral vector production. The quality, potency, and yield of the final therapeutic product are heavily dependent on the robustness of upstream processes, making its optimization essential. Increasing complexity in cell and gene therapies has driven the demand for specialized bioreactors, media formulations, and process monitoring tools, elevating the significance of upstream steps. This stage also involves rigorous control of culture conditions to maintain cell viability and functionality, directly impacting therapeutic efficacy. Furthermore, scalability challenges inherent in upstream workflows necessitate advanced technologies and skilled expertise, often requiring contract manufacturers equipped with cutting-edge facilities to meet Good Manufacturing Practice (GMP) standards. Innovations such as single-use bioreactors and closed-system platforms reduce contamination risks and facilitate rapid process transfer, reinforcing upstream processing's critical role. Although downstream processing and quality control are indispensable for purification and product release, their scope is contingent on the input quality from upstream operations. Packaging and distribution are vital for maintaining product integrity but represent a smaller portion of overall manufacturing complexity. Consequently, upstream processing continues to dominate driven by its foundational importance in defining the success and reproducibility of cell and gene therapies.

By Service Provider: Contract Development and Manufacturing Organizations (CDMOs) Drive Market Growth Through Specialized Expertise and Capacity

In terms of By Service Provider, Contract Development and Manufacturing Organizations (CDMOs) contribute the highest share of the Cell and Gene Therapy Manufacturing Services market, primarily because they offer the specialized expertise and scalable infrastructure essential for navigating the complexities of manufacturing highly personalized biologics. Many small and mid-sized biotech companies developing innovative therapies lack the capital-intensive facilities and regulatory experience required to manufacture at commercial scale, making CDMOs the preferred partner. CDMOs focus exclusively on providing flexible, tailored services across development and commercial production, allowing clients to accelerate their timelines without investing heavily in their own manufacturing capabilities. Additionally, the growing pipeline of cell and gene therapies has intensified competition for in-house capacity, prompting increasing reliance on external manufacturing partners to meet clinical and commercial demands. CDMOs continually invest in state-of-the-art technologies, skilled workforce, and GMP-compliant processes, which not only enhances product quality but also mitigates risks associated with scale-up and regulatory approval. Technology providers and in-house units serve niche but important roles, yet they are often constrained by limited scale or focused more on innovation than large-scale manufacturing. The shifting industry paradigm towards outsourcing to trusted CDMOs is driven by the need for cost efficiency, speed to market, and compliance adherence, positioning CDMOs as the central growth engine in this segment.

Regional Insights:

Dominating Region: North America

In North America, the dominance in Cell and Gene Therapy Manufacturing Services stems from a well-established biotech and pharmaceutical ecosystem, complemented by robust government support and regulatory frameworks. The U.S. Food and Drug Administration (FDA)'s progressive policies enable faster approvals and greater innovation, fostering an environment where both startups and established players thrive. The presence of major industry hubs like Boston and the San Francisco Bay Area facilitates strong collaboration between research institutions, contract development and manufacturing organizations (CDMOs), and biotech firms. Leading companies such as Lonza, Catalent, and Thermo Fisher Scientific have significantly contributed by offering advanced capabilities in viral vector production, cell processing, and quality assurance. Furthermore, strong trade relationships and access to venture capital amplify North America's influence in the global market.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific region exhibits the fastest growth in Cell and Gene Therapy Manufacturing Services, driven by expanding healthcare infrastructure, increasing government initiatives, and rising investments in biotechnology. Countries such as China, Japan, and South Korea are significantly ramping up capacity to meet both domestic demand and export opportunities. Supportive policies, such as China's "Made in China 2025" plan and Japan's regulatory incentives for regenerative medicine, accelerate technological advancements and market entry. Local players like WuXi AppTec (China) and Samsung Biologics (South Korea) are scaling up manufacturing capabilities and bringing world-class services to the region. Additionally, this region benefits from cost-competitive production and growing talent pools, attracting partnerships and outsourcing from global pharma companies seeking to diversify supply chains and reduce costs.

Cell and Gene Therapy Manufacturing Services Market Outlook for Key Countries

United States

The United States' market remains a global innovation leader with numerous clinical trials and FDA-approved therapies spearheading demand for advanced manufacturing services. Major players including Catalent, Thermo Fisher Scientific, and Novartis's manufacturing units leverage cutting-edge technologies such as automated bioreactors and gene editing platforms. The country's strong intellectual property framework and substantial investment into cell and gene therapy R&D support rapid commercialization and expansion of manufacturing networks.

Germany

Germany boasts a highly mature biotech industry combined with strong governmental research funding and favorable regulatory policies from the European Medicines Agency (EMA). Miltenyi Biotec and Bayer are notable contributors, providing integrated manufacturing solutions ranging from cell processing to viral vector production. The country's emphasis on quality standards and precision engineering enhances product reliability for clinical and commercial manufacturing.

China

China is transforming into a significant manufacturing hub due to aggressive government incentives, expanding infrastructure, and increased domestic demand for advanced therapies. WuXi AppTec and Pharma Legacy lead the market by offering scalable, GMP-compliant facilities, facilitating easier access to gene therapies for China's large patient population. The government's streamlined approval process and strategic focus on biotechnology innovation encourage foreign partnerships and local start-up growth.

Japan

Japan continues to lead in regenerative medicine and cell therapy manufacturing, supported by the Pharmaceuticals and Medical Devices Agency (PMDA)'s expedited review processes. Companies like Takeda and Fujifilm cellular dynamics have advanced manufacturing processes tailored to personalized medicine. Strong collaborations between academia and industry promote continuous innovation, with an emphasis on safety and quality controls to meet both local and international standards.

South Korea

South Korea's market is rapidly evolving, driven by favorable policies such as tax incentives and priority review for regenerative product approvals. Samsung Biologics and Celltrion are at the forefront, scaling up capacities in viral vector manufacturing and cell therapy production. South Korea's strategic government initiatives support export growth and positioning the country as a global CDMO hub that meets the increasing demand for cell and gene therapies worldwide.

Market Report Scope

Market Segmentation

Therapy Type Insights (Revenue, USD, 2021 - 2033)

• Cell Therapy
• Gene Therapy
• Combination Therapy
• Other Modalities

Process Type Insights (Revenue, USD, 2021 - 2033)

• Upstream Processing
• Downstream Processing
• Quality Control and Testing
• Packaging and Distribution
• Others

Service Provider Insights (Revenue, USD, 2021 - 2033)

• Contract Development and Manufacturing Organizations (CDMOs)
• In-house Manufacturing Units
• Technology Providers
• Others

Regional Insights (Revenue, USD, 2021 - 2033)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Catalent Pharma Solutions
• Lonza Group AG
• Thermo Fisher Scientific
• WuXi AppTec
• Fujifilm Cellular Dynamics
• Novasep
• Hitachi Chemical Advanced Therapeutics Solutions
• Samsung Biologics
• Cellectis
• LanzaTech
• Brammer Bio
• KBI Biopharma
• Vetter Pharma International
• Paragon Bioservices
• Miltenyi Biotec